Saturday, June 27, 2020 9:02:57 AM
$AIM
if Roswell PRs on this trial saying Ampligen has shown to be effective and safe in cancer patients with COVID-19 that these trials will be implemented in mass quantities in several countries. An EUA will be granted by the FDA...remember the 2 drugs that have already received it, which would you rather have if you were a 75 year old COVID-19, cancer and diabetic patient? Would you choose Remdesivir? How about hydroxychloroquine? Or Ampligen that has already been deemed safe and effective on the “train wreck COVID-19 cases”. Equels mentioned in May that the Roswell COVID-19 trials were a nice surprise. AIM didn’t do anything to initiate this which tells me Roswell already knows it’s effective and they stumbled across it by accident.
Equels has said in April interview that, “Ampligen could be the only effective treatment for SARS-CoV-2.”
Key takeaway as a shareholder, read the PR before you set a PT to sell at. If Roswell says it works our micro cap will become a mid cap!
Recent AIM News
- AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC • GlobeNewswire Inc. • 10/09/2024 01:00:00 PM
- AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis • GlobeNewswire Inc. • 10/03/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 07:55:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 05:12:28 PM
- AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/30/2024 12:22:43 PM
- AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment • GlobeNewswire Inc. • 09/27/2024 12:00:00 PM
- AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 04:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 07:45:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:45:37 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/11/2024 09:40:58 PM
- AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue • GlobeNewswire Inc. • 09/11/2024 01:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:43:58 AM
- AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
- AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:00:56 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:37:57 AM
- AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 08/13/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 01:41:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 01:39:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:05:15 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/30/2024 11:14:55 AM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 07/29/2024 01:15:00 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM